CD4 and myelodysplastic syndrome: In our previous study [7], we established a flow cytometric scoring system (FCMSS) to assist the diagnosis of low-grade MDS based on the proportion of CD34+ blasts and co-expressed immunophenotypes such as CD117, CD133, CD15, CD11b, CD4 and CD56.